Janelle DAlvise - Acasti Pharma President CEO
| ACST Stock | USD 3.19 0.22 7.41% |
CEO
Ms. Janelle DAlvise serves as President, Chief Executive Officer, Director of the Company. She has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Until recently, Ms. DAlvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. DAlvise was the CEO of the Sidney Kimmel Cancer Center, a drug discovery research institute. From 1995, she was also the CoFounder and Executive VPCOO of Metrika Inc., and in 1999 was the CoFounderPresidentCEO Chairman of NuGEN, Inc. Ms. DAlvise built both companies from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to 1995, Ms. DAlvise was a VP of Drug Development at SyntexRoche and Business Unit Director of their Pain and Inflammation business, and also VP of Commercial Operations at SYVA,, and began her career with Diagnostic Products Corporation since 2017.
| Age | 69 |
| Tenure | 7 years |
| Address | 3009 boulevard de la Concorde East, Laval, QC, Canada, H7E 2B5 |
| Phone | 450-687-2262 |
| Web | https://www.acastipharma.com |
Acasti Pharma Management Efficiency
The company has return on total asset (ROA) of (0.0792) % which means that it has lost $0.0792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4805) %, meaning that it created substantial loss on money invested by shareholders. Acasti Pharma's management efficiency ratios could be used to measure how well Acasti Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.25 in 2024, whereas Return On Tangible Assets are likely to drop (1.34) in 2024. Liabilities And Stockholders Equity is likely to gain to about 95.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Andrew MD | Akero Therapeutics | 57 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0792 |
Acasti Pharma Leadership Team
Elected by the shareholders, the Acasti Pharma's board of directors comprises two types of representatives: Acasti Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acasti. The board's role is to monitor Acasti Pharma's management team and ensure that shareholders' interests are well served. Acasti Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acasti Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Kottayil, Chief US | ||
| Robert CPA, Principal Officer | ||
| Prashant Kohli, Chief Officer | ||
| Amresh Kumar, VP Management | ||
| Janelle DAlvise, President CEO | ||
| Yves Lachance, VP Compliance | ||
| Carrie DAndrea, VP Operations | ||
| Pierre MD, COO CoFounder | ||
| Christine Pelletier, Director HR |
Acasti Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acasti Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0792 | ||||
| Current Valuation | 2.83 M | ||||
| Shares Outstanding | 9.4 M | ||||
| Shares Owned By Insiders | 16.02 % | ||||
| Shares Owned By Institutions | 13.48 % | ||||
| Number Of Shares Shorted | 1.11 K | ||||
| Price To Earning | 15.34 X | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 208.39 X |
Pair Trading with Acasti Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Acasti Stock
Moving against Acasti Stock
| 0.8 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.8 | ELDN | Eledon Pharmaceuticals | PairCorr |
| 0.77 | OGN | Organon | PairCorr |
| 0.53 | HOOK | Hookipa Pharma | PairCorr |
| 0.46 | MCRB | Seres Therapeutics | PairCorr |
The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.
The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Acasti Stock Analysis
When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.